In this study, we demonstrate that sustaining this treatment in the long term allows Avn-C to maintain its inhibitory effect on abnormal GSK3β activation, effectively regulating disease pathology and preventing disease progression in AD mouse models. The gene discussed is GSK3B; the disease is Alzheimer disease.